Dr Jack Bartram is a Consultant Paediatric Haematologist, Speciality Lead and the Clinical Director of the Specialised Integrated Haematology Malignancy Diagnostic Service at Great Ormond Street Hospital for Children (GOSH), London, UK. Nationally he is the Clinical Lead for infant leukaemia and minimal residual disease (MRD) in acute lymphoblastic leukaemia (ALL) network. He undertook a PhD at UCL Institute of Child Health, then a leukaemia research fellowship in the Genomic Medicine Programme at The Hospital for Sick Children “SickKids” in Toronto. Dr Bartram leads on molecular diagnostics within the Haematology Department at GOSH and has extensive expertise in high throughput sequencing for MRD analysis and was responsible for implementation of advanced genomic diagnostics and whole genome sequencing as standard of care for children with cancer at GOSH.

His research interest involves using advanced molecular diagnostic techniques to predict outcomes and find targets for novel therapies for children with haematological malignancies. Dr Bartram is co-principal investigator for CRUK funded REVEALL (RElapse-specific therapeutic Vulnerability Evaluation in childhood & young adult Acute Lymphoblastic Leukaemia) study and co-principal investigator on SAIL (Scientific Advances in Infant Leukaemia) study. He is currently the Clinical Lead for Haematological Malignancy Genomics in the NHSE North London Genomic Laboratory Hub and has been responsible for the implementation of advanced genomics and whole genome sequencing into clinical practice at GOSH.

Sameh El Fangary joined AstraZeneca in December 2020, bringing with him a wealth of experience in the pharmaceutical industry spanning 25 years. As a pharmacist holding a Master's in Business Administration, Sameh has held numerous roles across GCC and the UK gaining valuable expertise across a broad spectrum of disease areas including Primary Care, Specialties, Oncology, Rare Diseases, and Vaccines.

Inspired by AstraZeneca’s commitment to Science, Innovation, and Sustainability, and serving as the co-chair of the PHRMAG trade association, Sameh has played a pivotal role in fostering industry collaboration with both government and private sectors. His efforts have contributed significantly to transforming patient outcomes and advancing the global and regional agenda for the health of people, society, and the planet.

Ashraf Mallak is the Managing Director for MSD GCC. He has been recognized by Forbes Middle East as one of top 50 healthcare leaders in 2023 and 2022.

He is a member of the Executive Committee of The Pharmaceutical Research and Manufacturers Association Gulf (PHRMAG) and serves on the Board of Directors of the American Chamber of Dubai (AmCham).

Ashraf’s innate commercial and operational capabilities have helped MSD in the GCC to develop an outstanding commercial strategy utilizing digital data and analytics to make effective business decisions that benefit the company and its stakeholders.

Prior to his role as MD for the GCC, Ashraf served as Managing Director for KSA where he led the transformation of the business in the market. Under his leadership, the business in Saudi Arabia grew by 110%. He also led EEMEA regional commercial operations where he worked closely with markets and the global center of excellence at MSD to drive the execution of the company’s data and analytics capabilities as well as the deployment of a rapid response automated tool across EEMEA markets.

Ashraf joined MSD in 2002 and held several local and regional roles across sales, marketing, market access, business unit management, commercial and operations and general management.